EP4098256
Skömmtunaráætlun fyrir S1P viðtaka-örva
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
21.12.2009EP published:
26.2.2025EP application number:
22187007.4
EP translation filed:
19.3.2025Grant published:
15.4.2025EPO information:
European Patent Register
Max expiry date:
20.12.2029Expiry date:
20.12.2026Next due date:
31.12.2026
Title in English:
DOSAGE REGIMEN FOR A S1P RECEPTOR AGONISTLanguage of the patent:
English
Timeline
Today
21.12.2009EP application
26.2.2025EP Publication
19.3.2025Translation submitted
15.4.2025Registration published
20.12.2026Expires
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, 4056 Basel, CH
Inventor
Name:
SCHMOUDER, RobertAddress:
East Hanover, US
Name:
DUMORTIER, ThomasAddress:
Basel, CH
Name:
DAVID, OlivierAddress:
Basel, CH
Name:
LOOBY, MichaelAddress:
Basel, CH
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
139672 PDate:
22.12.2008Country:
US
Number:
218530 PDate:
19.6.2009Country:
US
Number:
246715 PDate:
29.9.2009Country:
US
Supplementary protection
SPC number:
SPC510
Classification
Categories:
A61K 31/137, A61P 37/00, A61P 37/06, A61K 31/135, A61K 31/138, A61K 31/661
Annual fees
Number
Paid
Expires
Payer
Number: 17
Paid: 19.12.2025
Expires: 20.12.2026
Payer: Árnason Faktor ehf.